Matches in SemOpenAlex for { <https://semopenalex.org/work/W3108411734> ?p ?o ?g. }
- W3108411734 endingPage "325" @default.
- W3108411734 startingPage "308" @default.
- W3108411734 abstract "Abstract The one-year and median overall survival (mOS) rates of advanced gastroesophageal adenocarcinomas (GEA) are ∼50% and <12 months, respectively. Baseline spatial and temporal molecular heterogeneity of targetable alterations may be a cause of failure of targeted/immunooncologic therapies. This heterogeneity, coupled with infrequent incidence of some biomarkers, has resulted in stalled therapeutic progress. We hypothesized that a personalized treatment strategy, applied at first diagnosis then serially over up to three treatment lines using monoclonal antibodies combined with optimally sequenced chemotherapy, could contend with these hurdles. This was tested using a novel clinical expansion-platform type II design with a survival primary endpoint. Of 68 patients by intention-to-treat, the one-year survival rate was 66% and mOS was 15.7 months, meeting the primary efficacy endpoint (one-sided P = 0.0024). First-line response rate (74%), disease control rate (99%), and median progression-free survival (8.2 months) were superior to historical controls. The PANGEA strategy led to improved outcomes warranting a larger randomized study. Significance: This study highlights excellent outcomes achieved by individually optimizing chemotherapy, biomarker profiling, and matching of targeted therapies at baseline and over time for GEA. Testing a predefined treatment strategy resulted in improved outcomes versus historical controls. Therapeutic resistance observed in correlative analyses suggests that dual targeted inhibition may be beneficial. This article is highlighted in the In This Issue feature, p. 211" @default.
- W3108411734 created "2020-12-07" @default.
- W3108411734 creator A5010010203 @default.
- W3108411734 creator A5015703898 @default.
- W3108411734 creator A5025052150 @default.
- W3108411734 creator A5031217394 @default.
- W3108411734 creator A5038171309 @default.
- W3108411734 creator A5049759474 @default.
- W3108411734 creator A5053712180 @default.
- W3108411734 creator A5064525249 @default.
- W3108411734 creator A5064760448 @default.
- W3108411734 creator A5065948260 @default.
- W3108411734 creator A5065952158 @default.
- W3108411734 creator A5068637029 @default.
- W3108411734 creator A5070440578 @default.
- W3108411734 creator A5076555423 @default.
- W3108411734 creator A5076750814 @default.
- W3108411734 creator A5077771845 @default.
- W3108411734 creator A5079608944 @default.
- W3108411734 creator A5080090747 @default.
- W3108411734 creator A5084293728 @default.
- W3108411734 creator A5084809433 @default.
- W3108411734 creator A5084810345 @default.
- W3108411734 creator A5090156519 @default.
- W3108411734 creator A5090997402 @default.
- W3108411734 creator A5091316016 @default.
- W3108411734 date "2021-02-01" @default.
- W3108411734 modified "2023-10-18" @default.
- W3108411734 title "Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease" @default.
- W3108411734 cites W1594731676 @default.
- W3108411734 cites W1758612015 @default.
- W3108411734 cites W1877969491 @default.
- W3108411734 cites W1965205681 @default.
- W3108411734 cites W1966643394 @default.
- W3108411734 cites W1982244230 @default.
- W3108411734 cites W2000572239 @default.
- W3108411734 cites W2008322008 @default.
- W3108411734 cites W2025016054 @default.
- W3108411734 cites W2025501584 @default.
- W3108411734 cites W2049309222 @default.
- W3108411734 cites W2064027682 @default.
- W3108411734 cites W2081367341 @default.
- W3108411734 cites W2098785500 @default.
- W3108411734 cites W2100439220 @default.
- W3108411734 cites W2104287359 @default.
- W3108411734 cites W2104759721 @default.
- W3108411734 cites W2109498035 @default.
- W3108411734 cites W2110887292 @default.
- W3108411734 cites W2111237964 @default.
- W3108411734 cites W2115842444 @default.
- W3108411734 cites W2119540121 @default.
- W3108411734 cites W2119746400 @default.
- W3108411734 cites W2129801498 @default.
- W3108411734 cites W2130867283 @default.
- W3108411734 cites W2150575159 @default.
- W3108411734 cites W2152362765 @default.
- W3108411734 cites W2155167083 @default.
- W3108411734 cites W2156394972 @default.
- W3108411734 cites W2160373161 @default.
- W3108411734 cites W2160981405 @default.
- W3108411734 cites W2163774814 @default.
- W3108411734 cites W2165411051 @default.
- W3108411734 cites W2168103287 @default.
- W3108411734 cites W2168110569 @default.
- W3108411734 cites W2171136968 @default.
- W3108411734 cites W2178051497 @default.
- W3108411734 cites W2347070489 @default.
- W3108411734 cites W2510561646 @default.
- W3108411734 cites W2525616756 @default.
- W3108411734 cites W2556376431 @default.
- W3108411734 cites W2558269388 @default.
- W3108411734 cites W2564210860 @default.
- W3108411734 cites W2570401594 @default.
- W3108411734 cites W2598685895 @default.
- W3108411734 cites W2618723848 @default.
- W3108411734 cites W2622499649 @default.
- W3108411734 cites W2758552192 @default.
- W3108411734 cites W2763498516 @default.
- W3108411734 cites W2773022455 @default.
- W3108411734 cites W2793114790 @default.
- W3108411734 cites W2793364080 @default.
- W3108411734 cites W2793920305 @default.
- W3108411734 cites W2794400308 @default.
- W3108411734 cites W2800224623 @default.
- W3108411734 cites W2804957989 @default.
- W3108411734 cites W2806614796 @default.
- W3108411734 cites W2883552436 @default.
- W3108411734 cites W2884883038 @default.
- W3108411734 cites W2889646458 @default.
- W3108411734 cites W2892163061 @default.
- W3108411734 cites W2897154408 @default.
- W3108411734 cites W2898197409 @default.
- W3108411734 cites W2900826672 @default.
- W3108411734 cites W2900894539 @default.
- W3108411734 cites W2907345836 @default.
- W3108411734 cites W2908573150 @default.
- W3108411734 cites W2912403850 @default.
- W3108411734 cites W2913250085 @default.